Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
narazaciclib (ON 123300)
i
Other names:
ON 123300, ON-123300, HX 301
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Twitter
Trials
Company:
HanX Biopharma, Onconova
Drug class:
CDK4 inhibitor, CDK6 inhibitor, ARK5 inhibitor
Related drugs:
‹
palbociclib (198)
abemaciclib (62)
ribociclib (55)
dalpiciclib (8)
DSP-2033 (8)
trilaciclib (3)
PRT3645 (3)
P1446A-05 (3)
RGT-419B (2)
CS3002 (1)
FCN-437 (1)
GLR2007 (1)
PF-06873600 (1)
G1T38 (1)
palbociclib (198)
abemaciclib (62)
ribociclib (55)
dalpiciclib (8)
DSP-2033 (8)
trilaciclib (3)
PRT3645 (3)
P1446A-05 (3)
RGT-419B (2)
CS3002 (1)
FCN-437 (1)
GLR2007 (1)
PF-06873600 (1)
G1T38 (1)
›
Associations
(2)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MYC overexpression
Hepatocellular Cancer
MYC overexpression
Hepatocellular Cancer
ON 123300
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ON 123300
Sensitive
:
D
AACR 2023 - 1wk
ON 123300
Sensitive: D – Preclinical
AACR 2023 - 1 week
ON 123300
Sensitive
:
D
AACR 2023 - 1 week - (New D)
NUAK1 overexpression
Hepatocellular Cancer
NUAK1 overexpression
Hepatocellular Cancer
ON 123300
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ON 123300
Sensitive
:
D
AACR 2023 - 1wk
ON 123300
Sensitive: D – Preclinical
AACR 2023 - 1 week
ON 123300
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login